Personalized Treatment and Management in Dermatology

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 2288

Special Issue Editors


E-Mail Website
Guest Editor
1. Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
2. Department of Medical Biotechnology, University of Siena, 53100 Siena, Italy
Interests: clinical dermatology; autoimmune bullous diseases; inflammatory or autoinflammatory diseases; hidradenitis suppurativa; atopic dermatitis; histopathology; immunopathology; genodermatoses

E-Mail Website
Guest Editor
Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy
Interests: clinical or molecular genetics and immunobiology of autoimmune and autoinflammatory skin disorders including, among others, hidradenitis suppurativa and pyoderma gangrenosum; genetics of infectious diseases; genodermatoses
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Personalized (or precision) medicine can be defined as a medical model whereby health interventions are tailored based on the individual characteristics of each patient. This term implies the incorporation of a wide array of “private” data, including clinical, lifestyle, genetic and biomarker information, thus going beyond the classical “signs-and-symptoms” approach. The four principles of personalized medicine are as follows: (i) prediction and prevention of the disease; (ii) precise diagnosis; (iii) personalized interventions; (iv) and participatory role of the patients in health decisions.

Dermatology has been one of the most involved fields of medicine in new technologies and precision medicine, as attested by the tremendous scientific advances during the last 20 years. The deep phenotyping of patients at different levels (from medical history to functional diagnostics, immunology/histology and omics) are revolutionizing our clinical practice, providing an opportunity to apply artificial intelligence (AI) and machine learning algorithms to this vast dataset to create prognostic/diagnostic models and predict treatment response.

The aim of this Special Issue is to gather articles and new ideas on the topic of personalized medicine in the field of immune-mediated inflammatory skin diseases and oncodermatology. Both clinical and basic research studies are to be considered to offer readers a wider perspective of the field with a focus on prognostic and/or diagnostic biomarker discovery, genetic and omic approaches, individual response to treatment, patient-related outcomes and novel machine learning algorithms.

Original research and reviews will be particularly appreciated. We look forward to your contributions to provide update progress on this topic.

Dr. Maurizio Romagnuolo
Dr. Chiara Moltrasio
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammatory or autoinflammatory skin diseases
  • autoimmune disorders
  • melanoma and non-melanoma skin cancers
  • multi-omics approaches
  • prognostic or diagnostic biomarkers
  • pharmacogenomics
  • targeted treatments
  • artificial intelligence
  • machine learning algorithms

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 2693 KiB  
Review
Blocking the IL-4/IL-13 Axis versus the JAK/STAT Pathway in Atopic Dermatitis: How Can We Choose?
by Laura Calabrese, Martina D’Onghia, Laura Lazzeri, Giovanni Rubegni and Elisa Cinotti
J. Pers. Med. 2024, 14(7), 775; https://doi.org/10.3390/jpm14070775 - 22 Jul 2024
Viewed by 1993
Abstract
Atopic dermatitis (AD) is an immune-mediated skin disorder with a chronic-relapsing course and a multifactorial pathogenesis. In contrast to the traditional concept of AD as solely a type 2 immune-activated disease, new findings highlight the disease as highly heterogeneous, as it can be [...] Read more.
Atopic dermatitis (AD) is an immune-mediated skin disorder with a chronic-relapsing course and a multifactorial pathogenesis. In contrast to the traditional concept of AD as solely a type 2 immune-activated disease, new findings highlight the disease as highly heterogeneous, as it can be classified into variable phenotypes based on clinical/epidemiological or molecular parameters. For many years, the only therapeutic option for moderate–severe AD was traditional immunosuppressive drugs. Recently, the area of systemic therapy of AD has significantly flourished, and many new substances are now marketed, licensed, or in the last step of clinical development. Biological agents and small molecules have enriched the therapeutic armamentarium of moderate-to-severe AD, such as dupilumab, tralokinumab, lebrikizumab (monoclonal antibodies targeting the IL-4/13 pathway), abrocitinib, upadacitinib, and baricitinib (JAK inhibitors). Indeed, the AD treatment paradigm is now split into two main approaches: targeting the IL-4/13 axis or the JAK/STAT pathway. Both approaches are valid and have strong evidence of preclinical and clinical efficacy. Therefore, the choice between the two can often be difficult and represents a major challenge for dermatologists. Indeed, several important factors must be taken into account, such as the heterogeneity of AD and its classification in phenotypes, patients’ comorbidities, age, and personal preferences. The aim of our review is to provide an overview of the clinical and molecular heterogeneities of AD and to explore the factors and parameters that, in clinical practice, may help inform clinical decision-making. Full article
(This article belongs to the Special Issue Personalized Treatment and Management in Dermatology)
Show Figures

Figure 1

Back to TopTop